Healthcare / Medical Devices / Signal Release

Press Release

Pheonix Research Releases 2026–2033 Blood Group Typing Forecast: USD 4.60 Billion at 9.17 Per Cent, 1.34 Times the Device Market

· Healthcare

FOR IMMEDIATE RELEASE

18 November 2026 — Pheonix Research has published its 2026–2033 forecast for the global blood group typing market, modelling USD 2.28 billion in 2025 rising to USD 4.60 billion in 2033: a compound annual growth rate of 9.17 per cent and 2.02 times the base year.

The test that gates every transfusion is growing faster than the devices it depends on. Pheonix models the global medical devices market at USD 520.00 billion in 2025 rising to USD 884.11 billion in 2033 at 6.86 per cent. Blood group typing compounds at 1.34 times that rate — and yet, because the typing layer is so small, its share of device value moves only from 0.438 per cent to 0.520 per cent: 8.2 basis points in eight years.

“This is a market where the growth is real and the base is small, and both facts matter to anyone planning against it,” said Pheonix Research’s healthcare and medical devices research team. “Typing is consumed before every transfusion and every transplant workup, so its demand tracks clinical activity rather than device capex. That gives it a faster growth rate than the device market and a share of it that stays below six-tenths of one per cent the whole way through the forecast.”

Key findings

  • Blood group typing: USD 2.28 billion in 2025 to USD 4.60 billion in 2033 — 9.17 per cent CAGR, 2.02 times the base year.
  • The medical devices market around it: USD 520.00 billion to USD 884.11 billion, at 6.86 per cent.
  • Growth multiple: typing compounds at 1.34 times the device market.
  • Share of device value: 0.438 per cent to 0.520 per cent — an 8.2 basis point gain.
  • The report describes the market as moderately consolidated with high competitive intensity, and identifies automated analysers, PCR-based systems, microarrays and next-generation sequencing as the technologies reshaping it. Ten tier-one players are profiled, including BD and Bio-Rad Laboratories.
  • This edition publishes no unit series — no test counts and no reagent volumes. It is a value model.

“The competitive consequence is the one to act on,” the team added. “A small, moderately consolidated market growing a third faster than the device industry is a market where the reagent and consumable line carries the economics and where the technology transition — manual to automated to molecular — is what reorders position. Nobody wins this on price alone, because the buyer is not shopping on price; they are buying a result that has to be right.”

The assumption that carries the forecast

Both series are Pheonix value models on the same 2025 base and the same 2033 horizon, and the share line is one divided by the other. If blood group typing compounded at 7.5 per cent rather than 9.17 per cent, 2033 would be USD 4.07 billion instead of USD 4.60 billion and it would barely hold its share of the device market rather than gain. The forecast is a statement about the value of testing, not about donor numbers or transfusion volumes, neither of which this edition models.

Report details

  • Title: Global Blood Group Typing Market Report, Size and Forecast 2026-2033
  • Base year: 2025  ·  Forecast horizon: to 2033
  • Coverage: global
  • Chapters: Table of Contents, Competitive Landscape, Value Chain, Investment Activity, Technology & Innovation, Market Risk, Regulatory Landscape
  • Availability: Global Blood Group Typing Market Report 2026-2033

About Pheonix Research

Pheonix Research publishes market intelligence on a live graph of more than 500 market, segment, industry, company and press-release nodes, translating market signals into role-specific decisions for procurement, strategy and executive teams. Each market report is modelled on stated assumptions and publishes the assumption that carries its forecast.

Media contact

Media and research enquiries: [email protected]
Commercial and licensing: [email protected]

— Ends —